Eyesure Medical aims to provide patients with treatment for cancerous tumors

 Eyesure Medical, a company engaged in the development and research of medical equipment for the treatment of tumors, aims to provide patients with treatment for cancerous tumors, and it seems that they are doing just that. Last night the company announced successful interim results in a study concerning the treatment of cancerous tumors in the kidneys. Is this a real promise or could the storm be like that of the other biotech companies?
The company's stock jumped up to 1000% in late trading on Wall Street and ended it up 400%. This is after the study conducted at Bnei Zion Hospital found a rate of 89.5% non-recurrence in the treatment of kidney tumors using the company's ProSense system. Aysure's Prosense is a tiny and invasive medical device that seeks to destroy tumors by freezing them in a process called cryoablation.
Why is data so important? In the past twenty years, the incidence of kidney tumors has increased in the United States and abroad. According to the American Cancer Society, each year, there are 79,000 new cases of kidney cancer, leading to an average of 14,000 deaths.
With the publication of this data, iSure proves that it can treat cancerous tumors safely and effectively. The jolt of positive news along with the fact that the company is undervalued caused the shares to rise sharply. Before the price spike, Isure had a market capitalization of just $35 million. Also, expectations were low, apparently catching the market off guard. The company debuted at the end of 2021 with a double-digit share price and fell as low as $0.75 today, before rising to more than $6 in late trading.
However, it should be remembered that cancer treatment is no small thing and the way to know if the experiment was really successful to the level that it will start being offered to the public is still a long way off. Almost all biotech companies jump after good research results but quite a few of them have gone back all the way down. The announcement from Eassure Medical looks promising but at least another update or two from the company is needed to substantiate the stock's rise.